Minerva Neurosciences

Minerva Neurosciences unveils 380-patient Phase 3 trial for roluperidone at LifeSci KOL event. First patient Q2 2026, results H2 2027. Stock up 3%.

Minerva Neurosciences Details Phase 3 Roluperidone Trial at LifeSci KOL Event — First Patient Expected Q2 2026

WESTERN DIGITAL

Seagate Technology Holdings

WD unveils $20+ EPS target at Innovation Day 2026, outlines 100TB HAMR roadmap to 2029. New $4B buyback authorized.

Western Digital Targets $20+ EPS, Unveils 100TB HAMR Roadmap at Innovation Day 2026

INTEL

NVIDIA

CISCO SYSTEMS

TAIWAN SEMICONDUCTOR MANUFACTURING CO

Intel CEO Lip-Bu Tan reveals 7-8% monthly yield gains on 18A node and new customer interest at Cisco AI Summit. Here's what it means for the foundry turnaround.

Intel CEO Says Customers 'Knocking on the Door' for 18A Chips as Foundry Turnaround Gains Traction

Merck & Co.

ELI LILLY &

PFIZER

Moderna

Merck beats Q4 with EPS $2.04 but guides 2026 below Street at $5-$5.15. Gardasil down 39% as China shipments halted. Keytruda hits $31.7B.

Merck Beats Q4 Estimates But Guides Low as Gardasil Headwinds Persist

RELX

THOMSON REUTERS CORP /CAN/

Salesforce

INTUIT

ADOBE

Snowflake

WORKIVA

LEGALZOOM.COM

OMNICOM GROUP

INTERPUBLIC GROUP OF COMPANIES

Anthropic's Claude legal plugin sent RELX, Thomson Reuters, and SAP tumbling 10%+ as AI disruption fears grip software sector. What investors need to know.

Anthropic's Legal Plugin Triggers Carnage in Software Stocks: RELX, Thomson Reuters, SAP Hammered

Pharming Group

NOVARTIS

Pharming guides $405M-$425M for 2026 at Investor Day, touts two billion-dollar pipeline programs despite FDA pediatric setback. Stock down 19%.

Pharming Guides to $405M-$425M Revenue at 2026 Investor Day, Eyes Two Billion-Dollar Pipeline Programs

News